News

New cancer target draws €259m
Enlarge image

BusinessUK

New cancer target draws €259m

11.12.2012 - British pharma GlaxoSmithKline fosters its transatlantic ties. Texas-based MD Anderson will receive €259m for a cancer immune therapy programme.

GlaxoSmithKline (GSK) secured a promising cancer immune therapy programme by collaborating with University of Texas MD Anderson from Houston (US). The deal, which allots GSK worldwide exclusive rights, was been made public on 7 December. In total, the pharma company could pay more than €259m in upfront and milestone payments, excluding the royalties of possible therapeutic antibody sales.

The programme in question has been established by former MD Anderson professor Yong-Jun Liu who is now working at the Baylor Research Institute in Dallas. Liu found that an activation of the T cell receptor OX40 (CD134) on the surface of dendritic cells improves the chances of an immune attack mediated by these cells: "T cell recognition of a tumour antigen is not enough to activate the T cells against cancer cells, they need a secondary signal to tell them “that antigen you have is a bad thing, you have to attack,'“ Liu said. Hence, he and his team screened for antibodies that could mimic the natural activator OX40L, which enables amplification of Th2 cell differentiation upon binding to its receptor. Right now the candidates have been boiled down to half a dozen. The collaboration with GSK in this late preclinical stage comes as no surprise for Liu: "It is gratifying to see this important step towards translating a basic science discovery into a potential new therapy that can proceed to clinical trial.“

The agreement between academia and economy is the first pact for MD Anderson’s new Institute for Applied Cancer Science (IACS). This institute is one of several projects of the recently launched ‚Moon Shot Program’ that tries to advance discoveries from basic sciences into the clinic. Dubbed as the „nation’s No. 1 hospital for cancer care“, MD Anderson thinks that „the end of cancer is closer than you think.“ Other cancer types included in the Moon Shots Program are breast and ovarian cancers, leukaemia (AML/MDS as well as CLL), lung cancer, melanoma and prostate cancer.

It is not the first time that a company aims to target OX40. The human MAB oxelumab targets not the receptor but its ligand OX40L. After Phase II trails in allergic asthma patients failed, Roche's US subsidiary Genentech terminated the development of oxelumab (huMAb OX40L) with Danish Genmab in Q2/2011.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/new-cancer-drug-target-draws-eur259m.html

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • KAROLINSKA (S)7.85 SEK9.03%

FLOP

  • PROTHENA PLC (IE)38.59 USD-7.15%
  • MEDIGENE (D)8.15 EUR-6.21%
  • ADOCIA (F)56.55 EUR-5.10%

TOP

  • SYNAIRGEN (UK)35.00 GBP45.8%
  • BIOFRONTERA (D)3.24 EUR38.5%
  • SWEDISH ORPHAN BIOVITRUM (S)15.24 USD27.5%

FLOP

  • EVOCUTIS (UK)0.05 GBP-28.6%
  • THERAMETRICS (CH)0.03 CHF-25.0%
  • SERODUS (N)1.50 NOK-23.9%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.40 SEK1793.3%
  • NICOX (F)8.27 EUR339.9%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.30 SEK-87.9%
  • BB BIOTECH (D)44.10 EUR-83.1%
  • CYTOS (CH)0.25 CHF-80.3%

No liability assumed, Date: 04.05.2016